Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease

Trial Profile

Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 19 May 2017

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 18 May 2017 This trial has been discontinued in Sweden.
    • 22 Apr 2017 This trial has been discontinued in Poland (end date: 23 Feb 2017).
    • 01 Apr 2017 Trial has been discontinued in Belgium (End date:2017-02-23) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top